LOW INTERSTITIAL LUNG DISEASE EVENT RATE IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED POST HOC ANALYSIS OF DATA FROM THE TOFACITINIB CLINICAL DEVELOPMENT PROGRAM

被引：0

作者：

Citera, Gustavo ^{[1
]}

Mysler, Eduardo ^{[2
]}

Madariaga, Hugo ^{[3
]}

Cardiel, Mario H. ^{[4
]}

Castaneda, Oswaldo ^{[5
]}

Fischer, Aryeh ^{[6
]}

Richette, Pascal ^{[7
]}

Chartrand, Sandra ^{[8
]}

Park, Jin Kyun ^{[9
]}

Strengholt, Sander ^{[10
]}

Luis Rivas, Jose ^{[11
]}

Thorat, Amit ^{[12
]}

Girard, Tanya ^{[13
]}

Kwok, Kenneth ^{[14
]}

Wang, Lisy ^{[15
]}

Ponce de Leon, Dario ^{[16
]}

机构：

[1] Inst Rehabil Psicofis, Buenos Aires, DF, Argentina

[2] Org Med Invest, Buenos Aires, DF, Argentina

[3] Clin Sur, Arequipa, Peru

[4] Ctr Invest Clin Morelia, Morelia, Michoacan, Mexico

[5] Clin Anglo Amer, Lima, Peru

[6] Univ Colorado Denver, Dept Med, Denver, CO USA

[7] Hop Lariboisiere, AP HP, Dept Rheumatol, Paris, France

[8] Univ Montreal, Hop Maisonneuve Rosemont, Dept Med, Montreal, PQ, Canada

[9] Seoul Natl Univ Hosp, Dept Internal Med, Div Rheumatol, Seoul, South Korea

[10] Pfizer Inc, Capelle Aan Den Ijssel, Netherlands

[11] Pfizer SLU, Madrid, Spain

[12] Pfizer Ltd, Mumbai, Maharashtra, India

[13] Pfizer Inc, Montreal, PQ, Canada

[14] Pfizer Inc, New York, NY USA

[15] Pfizer Inc, Groton, CT 06340 USA

[16] Pfizer Inc, Lima, Peru

来源：

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S42 / S42

页数：1

共 50 条

[41] Effectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data
Kalyoncu, U.
Bilgin, E.
Erden, A.
Satis, H.
Tufan, A.
Tekgoz, E.
Ates, A.
Coskun, B. N.
Yagiz, B.
Kucuksahin, O.
Yazisiz, V.
Kimyon, G.
Bes, C.
Basibuyuk, C. S.
Alkan, S.
Cesur, T. Y.
Ertenli, I.
Kiraz, S.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2022, 40 (11) : 2071 - 2077
[42] JOINT-SPECIFIC RESPONSES TO TOFACITINIB AND ADALIMUMAB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STANDARD AND ORAL STRATEGY
Ciurea, Adrian
Distler, Oliver
Killeen, Tim
Akylbekova, Ermeg
Kwok, Kenneth
Wang, Lisy
Ospelt, Caroline
Frank-Bertoncelj, Mojca
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 742 - 743
[43] Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic
Provan, Sella Aarrestad
Ljung, Lotta
Kristianslund, Eirik Klami
Michelsen, Brigitte
Uhlig, Till
Jonmundsson, Thorarinn
Sexton, Joe
Gudbjornsson, Bjorn
Di Giuseppe, Daniela
Hetland, Merete Lund
Reynisdottir, Gudrun Bjork
Glintborg, Bente
Relas, Heikki
Aaltonen, Kalle
Kvien, Tore Kristian
Askling, Johan
JOURNAL OF RHEUMATOLOGY, 2024, 51 (11) : 1111 - 1118
[44] Discontinuation rate of Tofacitinib is similar when compared to TNF inhibitors in rheumatoid arthritis patients: Data from a rheumatoid arthritis cohort
Movahedi, Mohammad
Cesta, Angela
Li, Xiuying
Keystone, Edward
Bombardier, Claire
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 27 - 28
[45] The Recall Program: Data from a Multicenter Educational Event on Patients with Rheumatoid Arthritis
Delle Sedie, Andrea
Filippucci, Emilio
Epis, Oscar
Macchioni, Pierluigi
Tropea, Sebastiano
Bonali, Carlo
Canzoni, Marco
Iagnocco, Annamaria
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[46] The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials
Susan J. Bartlett
Clifton O. Bingham
Ronald van Vollenhoven
Christopher Murray
David Gruben
David A. Gold
David Cella
Arthritis Research & Therapy, 24
[47] The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials
Bartlett, Susan J.
Bingham, Clifton O.
van Vollenhoven, Ronald
Murray, Christopher
Gruben, David
Gold, David A.
Cella, David
ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
[48] Development of a Risk Nomogram Model for Identifying Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Xue, Jing
Hu, Wenfeng
Wu, Shuang
Wang, Jing
Chi, Shuhong
Liu, Xiaoming
FRONTIERS IN IMMUNOLOGY, 2022, 13
[49] Development of a risk indicator score for the identification of interstitial lung disease in patients with rheumatoid arthritis
Paulin, Francisco
Jennifer Doyle, Tracy
Francisco Mercado, Juan
Fassola, Leandro
Fernandez, Martin
Caro, Fabian
Laura Alberti, Maria
Crespo Espindola, Maria Elena
Buschiazzo, Emilio
REUMATOLOGIA CLINICA, 2021, 17 (04): : 207 - 211
[50] Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies
Dikranian, Ara H.
Gonzalez-Gay, Miguel A.
Wellborne, Frank
Alvaro-Gracia, Jose Maria
Takiya, Liza
Stockert, Lori
Paulissen, Jerome
Shi, Harry
Tatulych, Svitlana
Curtis, Jeffrey R.
RMD OPEN, 2022, 8 (01):

← 1 2 3 4 5 →